

Randall C Starling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2995791/publications.pdf>

Version: 2024-02-01

212
papers

16,502
citations

22153

59
h-index

16183

124
g-index

228
all docs

228
docs citations

228
times ranked

13514
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebral Microvascular Injury in Patients with Left Ventricular Assist Device: a Neuropathological Study. <i>Translational Stroke Research</i> , 2022, 13, 257-264.	4.2	7
2	Large animal models of heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2022, 27, 595-608.	3.9	9
3	Contemporary Trends of Clinical Outcomes in Primary Left Ventricular Assist Device Implantation and Postprocedure High-Risk Categories. <i>Journal of Cardiac Failure</i> , 2022, 28, 270-282.	1.7	1
4	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2022, 7, 17.	6.1	77
5	Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 916-923.	1.7	5
6	Left Atrial Circulatory Assistance in Simulated Diastolic Heart Failure Model: First in Vitro and in Vivo. <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	4
7	Postimplant Phosphodiesterase-5 Inhibitor Use in Centrifugal Flow Left Ventricular Assist Devices. <i>JACC: Heart Failure</i> , 2022, 10, 89-100.	4.1	9
8	Chronic Heart Failure: Diagnosis and Management beyond LVEF Classification. <i>Journal of Clinical Medicine</i> , 2022, 11, 1718.	2.4	6
9	Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. <i>Heart Failure Reviews</i> , 2022, 27, 1991-2003.	3.9	15
10	Incremental Value of Global Longitudinal Strain to Michigan Risk Score and Pulmonary Artery Pulsatility Index in Predicting Right Ventricular Failure Following Left Ventricular Assist Devices. <i>Heart Lung and Circulation</i> , 2022, 31, 1110-1118.	0.4	5
11	Incidence and Prognostic Implications of Readmissions Caused by Thrombotic Events After a Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2022, 11, e025342.	3.7	0
12	Demand for Mechanical Circulatory Support. , 2022, , 63-77.		0
13	Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?. <i>Journal of Cardiac Failure</i> , 2022, , .	1.7	0
14	Left atrial assist device function at various heart rates using a mock circulation loop. <i>International Journal of Artificial Organs</i> , 2021, 44, 465-470.	1.4	5
15	Left atrial assist device to treat patients with heart failure with preserved ejection fraction: Initial in Vitro study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 120-126.	0.8	23
16	Heart failure and COVID-19. <i>Heart Failure Reviews</i> , 2021, 26, 1-10.	3.9	152
17	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. <i>Nature Reviews Cardiology</i> , 2021, 18, 169-193.	13.7	589
18	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. <i>Heart Lung and Circulation</i> , 2021, 30, 786-794.	0.4	16

#	ARTICLE	IF	CITATIONS
19	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	1.7	4
20	Stage D Heart Failure With Preserved Ejection Fraction, Heart Transplantation, and Mechanical Circulatory Support. , 2021, , 276-289.		0
21	Device-based treatment options for heart failure with preserved ejection fraction. <i>Heart Failure Reviews</i> , 2021, 26, 749-762.	3.9	16
22	Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy. <i>Journal of Cardiac Failure</i> , 2021, 27, 368-372.	1.7	12
23	Obesity, inflammation, and heart failure: links and misconceptions. <i>Heart Failure Reviews</i> , 2021, , 1.	3.9	8
24	Impact of an electronic medical record-based appointment order on outpatient cardiology follow-up after hospital discharge. <i>Npj Digital Medicine</i> , 2021, 4, 77.	10.9	3
25	Left atrial assist device for heart failure with preserved ejection fraction: initial results with torque control mode in diastolic heart failure model. <i>Heart Failure Reviews</i> , 2021, , 1.	3.9	8
26	A case series of cardiac amyloidosis patients supported by continuousâ€flow left ventricular assist device. <i>ESC Heart Failure</i> , 2021, 8, 4353-4356.	3.1	7
27	Kinetics of generic tacrolimus in heart transplantation: A cautionary note. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 569-572.	0.6	4
28	ACE2, the Counter-Regulatory Reninâ€Angiotensin System Axis and COVID-19 Severity. <i>Journal of Clinical Medicine</i> , 2021, 10, 3885.	2.4	14
29	Medical Treatment of Heart Failure: Ignore the Ejection Fraction and Treat All?. <i>Journal of Cardiac Failure</i> , 2021, 27, 907-909.	1.7	7
30	Treating symptoms and reversing remodelling: clinical and echocardiographic <scp>1â€year</scp> outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation. <i>European Journal of Heart Failure</i> , 2021, 23, 1971-1978.	7.1	10
31	Needing to vent: best to pitch the vent before heart transplant. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 852-854.	1.0	0
32	Does Anyone Read Heart Failure Guidelines? Why You Should Read the Japanese Guideline!. <i>Journal of Cardiac Failure</i> , 2021, 27, 1445-1446.	1.7	0
33	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , 2021, 154, 123-126.	1.6	1
34	Cerebrovascular Events in Patients With Centrifugal-Flow Left Ventricular Assist Devices: Propensity Scoreâ€Matched Analysis From the Intermacs Registry. <i>Circulation</i> , 2021, 144, 763-772.	1.6	54
35	Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. <i>Heart</i> , 2021, , heartjnl-2020-318333.	2.9	3
36	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	2.7	3

#	ARTICLE	IF	CITATIONS
37	The Effects of Preserving Mitral Valve Function on a Left Atrial Assist Device: An In Vitro Mock Circulation Loop Study. <i>ASAIO Journal</i> , 2021, 67, 567-572.	1.6	7
38	Reply to "Benefits of transvenous mitral annuloplasty in heart failure with lower degrees of functional mitral regurgitation". <i>European Journal of Heart Failure</i> , 2021, 23, 1985-1986.	7.1	1
39	The Emergence of the HF and Critical Care Medicine Specialist: An Unmet Need That Needs a Rapid Solution. <i>Journal of Cardiac Failure</i> , 2021, , .	1.7	2
40	Clinical Courses of HeartMate II Left Ventricular Assist Device Thrombosis. <i>ASAIO Journal</i> , 2020, 66, 153-159.	1.6	5
41	Candidate Selection and Decision Making in Mechanical Circulatory Support. , 2020, , 31-39.		0
42	The Enemy Within. <i>Circulation</i> , 2020, 142, 1865-1870.	1.6	42
43	Obesity Predicts Survival After Cardiac Resynchronization Therapy Independent of Effect on Left Ventricular Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e007424.	3.9	1
44	Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation. <i>Journal of the American Heart Association</i> , 2020, 9, e015897.	3.7	24
45	Ischemic Stroke and Intracranial Hemorrhages During Impella Cardiac Support. <i>ASAIO Journal</i> , 2020, 66, e105-e109.	1.6	22
46	Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]). <i>Circulation</i> , 2020, 142, 2016-2028.	1.6	108
47	Updated definitions of adverse events for trials and registries of mechanical circulatory support: A consensus statement of the mechanical circulatory support academic research consortium. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 735-750.	0.6	101
48	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	4.1	39
49	<sc>Sacubitril/valsartan</sc> in patients <sc>post-left</sc> ventricular assist device implant: a <sc>single-centre</sc> case series. <i>European Journal of Heart Failure</i> , 2020, 22, 1490-1492.	7.1	6
50	Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. <i>American Journal of Transplantation</i> , 2020, 20, 2768-2780.	4.7	26
51	Cerebral Microembolization in Left Ventricular Assist Device Associated Ischemic Events. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104660.	1.6	4
52	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
53	Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , 2020, 26, 448-456.	1.7	146
54	Care for patients with ventricular assist devices and suspected <sc>COVID</sc>-19 infection. <i>European Journal of Heart Failure</i> , 2020, 22, 937-940.	7.1	7

#	ARTICLE	IF	CITATIONS
55	Cardiorenal Syndrome in a Patient with Mechanical Circulatory Support. , 2020, , 227-247.		0
56	Patient Population and Selection Criteria for Mechanical Circulatory Support. , 2020, , 131-139.		1
57	Dynamic prediction of left ventricular assist device pump thrombosis based on lactate dehydrogenase trends. ESC Heart Failure, 2019, 6, 1005-1014.	3.1	12
58	Atrial Tachyarrhythmias Among Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2019, 5, 459-466.	3.2	13
59	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	2.8	37
60	In-hospital red blood cell distribution width change in patients with heart failure. European Journal of Heart Failure, 2019, 21, 1659-1661.	7.1	14
61	Initiation of Angiotensin Receptor-Nepilysin Inhibitor in Heart Failure With Low Cardiac Output. Journal of the American College of Cardiology, 2019, 74, 2326-2327.	2.8	9
62	The Impact of Infection and Elevated INR in LVAD-Associated Intracranial Hemorrhage: A Case-Crossover Study. ASAIO Journal, 2019, 65, 545-549.	1.6	29
63	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
64	Minimally invasive biventricular mechanical circulatory support with Impella pumps as a bridge to heart transplantation: a first-in-the-world case report. ESC Heart Failure, 2019, 6, 552-554.	3.1	17
65	What Causes LVAD-Associated Ischemic Stroke? Surgery, Pump Thrombosis, Antithrombotics, and Infection. ASAIO Journal, 2019, 65, 775-780.	1.6	47
66	Heart Failure and Liver Disease. JACC: Heart Failure, 2019, 7, 87-97.	4.1	162
67	Standardized Psychosocial Assessment Before Left Ventricular Assist Device Implantation. Circulation: Heart Failure, 2019, 12, e005377.	3.9	30
68	The management of antibodies in heart transplantation: An ISHLT consensus document. Journal of Heart and Lung Transplantation, 2018, 37, 537-547.	0.6	114
69	Larissa Heart Failure Risk Score: a proposed simple score for risk stratification in chronic heart failure. European Journal of Heart Failure, 2018, 20, 614-616.	7.1	11
70	Hemodynamic factors associated with serum chloride in ambulatory patients with advanced heart failure. International Journal of Cardiology, 2018, 252, 112-116.	1.7	12
71	Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment. Trends in Cardiovascular Medicine, 2018, 28, 392-400.	4.9	29
72	Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. Journal of Heart and Lung Transplantation, 2018, 37, 706-714.	0.6	68

#	ARTICLE	IF	CITATIONS
73	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	7.1	42
74	Mitral Valve Stenosis: Still a Clinical Challenge?. <i>Cardiology</i> , 2018, 140, 45-46.	1.4	1
75	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	1.8	22
76	Utility of the Psychosocial Assessment of Candidates for Transplantation in Patients Undergoing Continuous-Flow Left Ventricular Assist Device Implantation. <i>Progress in Transplantation</i> , 2018, 28, 220-225.	0.7	10
77	Continuously Updated Estimation of Heart Transplant Waitlist Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 72, 650-659.	2.8	24
78	Prospective assessment of combined handgrip strength and Mini-Cog identifies hospitalized heart failure patients at increased post-hospitalization risk. <i>ESC Heart Failure</i> , 2018, 5, 948-952.	3.1	21
79	Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 673-683.	0.6	142
80	Adaptive CRT in patients with normal AV conduction and left bundle branch block: Does QRS duration matter?. <i>International Journal of Cardiology</i> , 2017, 240, 297-301.	1.7	18
81	Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	29
82	Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	42
83	Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval. <i>JACC: Heart Failure</i> , 2017, 5, 460-463.	4.1	12
84	Prognostic Utility of Right Ventricular Free Wall Strain in Low Risk Patients After Orthotopic Heart Transplantation. <i>American Journal of Cardiology</i> , 2017, 119, 1890-1896.	1.6	18
85	Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. <i>JACC: Heart Failure</i> , 2017, 5, 518-527.	4.1	159
86	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	4.1	84
87	Are Outcomes Related to Left Ventricular Assist Device Center Volume?. <i>JACC: Heart Failure</i> , 2017, 5, 700-702.	4.1	2
88	Stable coronary artery disease and left ventricular dysfunction: The role of revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 777-783.	1.7	1
89	Optimal Timing of Heart Transplant After HeartMate II Left Ventricular Assist Device Implantation. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1569-1576.	1.3	21
90	The axial continuous-flow blood pump: Bench evaluation of changes in flow associated with changes of inflow cannula angle. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 106-112.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). <i>American Journal of Cardiology</i> , 2017, 119, 78-83.	1.6	44
92	Usefulness of cell-mediated immune function in risk stratification for patients with advanced heart failure. <i>American Heart Journal</i> , 2017, 183, 35-39.	2.7	5
93	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	7.1	22
94	Tolvaptan in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1407-1408.	2.8	11
95	Large animal models to test mechanical circulatory support devices. <i>Drug Discovery Today: Disease Models</i> , 2017, 24, 47-53.	1.2	1
96	Discordance between 'actual' and 'scheduled' check-in times at a heart failure clinic. <i>PLoS ONE</i> , 2017, 12, e0187849.	2.5	10
97	A unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. <i>PLoS ONE</i> , 2017, 12, e0170456.	2.5	26
98	Abstract 21098: Variables From the CMS Heart Failure Readmission Model Poorly Predict 30-Day Rehospitalization Risk in Heart Failure Patients From a Large Academic Hospital System. <i>Circulation</i> , 2017, 136, .	1.6	0
99	Post-acute Care Trajectories in the First Year Following Hospital Discharge After Left Ventricular Assist Device Implantation. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 908-912.	2.5	3
100	Augmenting outcomes in advanced heart failure: a lot to learn. <i>European Journal of Heart Failure</i> , 2016, 18, 326-327.	7.1	0
101	Vagus Nerve Stimulation for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 149-158.	2.8	283
102	The Contribution to Hemodynamics Even at Very Low Pump Speeds in the HVAD. <i>Annals of Thoracic Surgery</i> , 2016, 101, 2260-2264.	1.3	10
103	Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease?. <i>JACC: Heart Failure</i> , 2016, 4, 689-697.	4.1	49
104	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	15
105	Reframing the association and significance of comorbidities in heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 744-758.	7.1	169
106	Recovery of Serum Cholesterol Predicts Survival After Left Ventricular Assist Device Implantation. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	10
107	Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>BMJ Open</i> , 2016, 6, e010201.	1.9	11
108	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) <i>TJ ETQq0 0 0 rgBT /Overlock 10 TF</i>	1.6	26

#	ARTICLE	IF	CITATIONS
109	Limitations to Chronic Right Ventricular Assist Device Support. <i>Annals of Thoracic Surgery</i> , 2016, 102, 651-658.	1.3	39
110	Cardiac Myosin Activators for the Treatment of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1456-1458.	2.8	6
111	Transient Hyponatremia During Hospitalization for Acute Heart Failure. <i>American Journal of Medicine</i> , 2016, 129, 620-627.	1.5	19
112	Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 956-963.	7.1	6
113	Prognostic role of cardiac power index in ambulatory patients with advanced heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 689-696.	7.1	35
114	Left Ventricular Assist Devices Ramp Studies. <i>JACC: Heart Failure</i> , 2015, 3, 300-302.	4.1	1
115	Current risks of HeartMate II pump thrombosis: Non-parametric analysis of Interagency Registry for Mechanically Assisted Circulatory Support data. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1527-1534.	0.6	56
116	Coagulopathy in Mechanical Circulatory Support: A Fine Balance. <i>Current Cardiology Reports</i> , 2015, 17, 114.	2.9	15
117	Renal Failure Requiring Dialysis Complicating Slow Continuous Ultrafiltration in Acute Heart Failure: Importance of Systolic Perfusion Pressure. <i>Journal of Cardiac Failure</i> , 2015, 21, 108-115.	1.7	9
118	Comparison of Left Ventricular Torsion and Strain With Biventricular Pacing in Patients With Underlying Right Bundle Branch Block Versus Those With Left Bundle Branch Block. <i>American Journal of Cardiology</i> , 2015, 115, 918-923.	1.6	4
119	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 66, 659-666.	2.8	123
120	Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions. <i>JACC: Heart Failure</i> , 2015, 3, 565-572.	4.1	48
121	Left ventricular assist device thrombosis in the setting of left ventricular recovery. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 622-623.	0.6	4
122	Does pulsatility matter in the era of continuous-flow blood pumps?. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 999-1004.	0.6	78
123	InÂvitro hemodynamic characterization of HeartMate II at 6000 rpm: Implications for weaning and recovery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 343-348.	0.8	14
124	A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. <i>American Heart Journal</i> , 2015, 169, 806-812.	2.7	44
125	Outcomes of Heart Transplant After Left Ventricular Assist Device Specific and RelatedÂinfection. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1292-1297.	1.3	46
126	Duration of Heart Failure Is an Important Predictor of Outcomes After Mechanical Circulatory Support. <i>Circulation: Heart Failure</i> , 2015, 8, 953-959.	3.9	21

#	ARTICLE	IF	CITATIONS
127	The HVAD Left Ventricular Assist Device. JACC: Heart Failure, 2015, 3, 818-828.	4.1	167
128	Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 1747-1761.	2.8	311
129	Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: Design and rationale of the ROADMAP clinical trial. American Heart Journal, 2015, 169, 205-210.e20.	2.7	32
130	Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure. American Journal of Cardiology, 2015, 115, 57-61.	1.6	111
131	Sacubitril-valsartan and the evolution of heart failure care. Cleveland Clinic Journal of Medicine, 2015, 82, 702-704.	1.3	0
132	Abstract 18412: Lactate Dehydrogenase Trends Predict Left Ventricular Assist Device Thrombosis. Circulation, 2015, 132, .	1.6	0
133	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. Circulation, 2015, 132, .	1.6	0
134	Abstract 17888: A Dynamically Updated Cardiac Transplant Waitlist Mortality Score. Circulation, 2015, 132, .	1.6	0
135	Abstract 18407: Identifying Patients With Acute Heart Failure who Require a Critical Care Admission: ASCEND-HF Insights. Circulation, 2015, 132, .	1.6	0
136	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. Circulation: Heart Failure, 2014, 7, 918-925.	3.9	42
137	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. Circulation, 2014, 130, 958-965.	1.6	41
138	Outcomes of Patients With Peripartum Cardiomyopathy Who Received Mechanical Circulatory Support. Circulation: Heart Failure, 2014, 7, 300-309.	3.9	70
139	Destination Therapy With Left Ventricular Assist Devices: For Whom and When?. Canadian Journal of Cardiology, 2014, 30, 296-303.	1.7	45
140	Less invasive versus conventional heart valve surgery in patients with severe heart failure. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 161-167.e6.	0.8	2
141	Unexpected Abrupt Increase in Left Ventricular Assist Device Thrombosis. New England Journal of Medicine, 2014, 370, 33-40.	27.0	743
142	Increase in Left Ventricular Assist Device Thrombosis. New England Journal of Medicine, 2014, 370, 1463-1466.	27.0	38
143	S100A1 in Human Heart Failure. Circulation: Heart Failure, 2014, 7, 612-618.	3.9	9
144	Does the UNOS Heart Transplant Allocation System Favor Men Over Women?. JACC: Heart Failure, 2014, 2, 347-355.	4.1	31

#	ARTICLE	IF	CITATIONS
145	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. <i>International Journal of Cardiology</i> , 2014, 172, 115-121.	1.7	96
146	Percutaneous Lead Dysfunction in the HeartMate II Left Ventricular Assist Device. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1373-1378.	1.3	24
147	An analysis of pump thrombus events in patients in the HeartWare ADVANCE bridge to transplant and continued access protocol trial. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 23-34.	0.6	421
148	Long-Term Mortality After Cardiac Allograft Vasculopathy. <i>JACC: Heart Failure</i> , 2014, 2, 281-288.	4.1	48
149	Frequency of Depression and Anxiety Before and After Insertion of a Continuous Flow Left Ventricular Assist Device. <i>American Journal of Cardiology</i> , 2014, 114, 433-440.	1.6	44
150	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.1	39
151	Preload Sensitivity in Cardiac Assist Devices. <i>Annals of Thoracic Surgery</i> , 2013, 95, 373-380.	1.3	44
152	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	4.1	22
153	Unplanned Hospital Readmissions After HeartMate II Implantation. <i>JACC: Heart Failure</i> , 2013, 1, 31-39.	4.1	84
154	Clinical outcomes with synchronized left ventricular pacing: Analysis of the adaptive CRT trial. <i>Heart Rhythm</i> , 2013, 10, 1368-1374.	0.7	139
155	Major Bleeding During HeartMate II Support. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2188-2196.	2.8	62
156	Cardiac Allograft Vasculopathy by Intravascular Ultrasound in Heart Transplant Patients. <i>JACC: Heart Failure</i> , 2013, 1, 389-399.	4.1	110
157	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	3.9	103
158	Left Ventricular Assist Devices: From the Bench to the Clinic. <i>Cardiology</i> , 2013, 125, 1-12.	1.4	18
159	Advanced heart failure: Transplantation, LVADs, and beyond. <i>Cleveland Clinic Journal of Medicine</i> , 2013, 80, 33-40.	1.3	10
160	Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: Results of the adaptive CRT trial. <i>Heart Rhythm</i> , 2012, 9, 1807-1814.e1.	0.7	223
161	A novel algorithm for individualized cardiac resynchronization therapy: Rationale and design of the adaptive cardiac resynchronization therapy trial. <i>American Heart Journal</i> , 2012, 163, 747-752.e1.	2.7	54
162	Implantable Cardiac Defibrillators and Sudden Death in Recent Onset Nonischemic Cardiomyopathy: Results From IMAC2. <i>Journal of Cardiac Failure</i> , 2012, 18, 675-681.	1.7	25

#	ARTICLE	IF	CITATIONS
163	Implantable Continuous-Flow Right Ventricular Assist Device: Lessons Learned in the Development of a Cleveland Clinic Device. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1746-1752.	1.3	34
164	Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 143, 1036-1042.	0.8	85
165	Potential Population for Long-Term Use of Left Ventricular Assist Devices. , 2012, , 11-21.		1
166	Results of the Post-U.S. Food and Drug Administration-Approval Study With a Continuous Flow Left Ventricular Assist Device as a Bridge to Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1890-1898.	2.8	434
167	Clinical and Demographic Predictors of Outcomes in Recent Onset Dilated Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1112-1118.	2.8	202
168	Surgical Treatment of Chronic Heart Failure. , 2011, , 802-817.		0
169	Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 569-574.e1.	0.8	87
170	Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1406-1413.	1.3	97
171	Inotropic Therapy for End-Stage Heart Failure Patients. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2010, 12, 409-419.	0.9	30
172	Are All Readmissions Bad Readmissions?. <i>New England Journal of Medicine</i> , 2010, 363, 297-298.	27.0	195
173	Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, S1-S39.	0.6	798
174	A review of dyspnea in acute heart failure syndromes. <i>American Heart Journal</i> , 2010, 160, 209-214.	2.7	58
175	Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure. <i>Circulation: Heart Failure</i> , 2009, 2, 320-324.	3.9	128
176	Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 589-596.	2.8	1,313
177	Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 600-607.	2.8	65
178	Insights From a Cardiac Resynchronization Optimization Clinic as Part of a Heart Failure Disease Management Program. <i>Journal of the American College of Cardiology</i> , 2009, 53, 765-773.	2.8	424
179	Sodium Nitroprusside for Advanced Low-Output Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 200-207.	2.8	184
180	The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2007, 28, 3076-3093.	2.2	336

#	ARTICLE	IF	CITATIONS
181	The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. <i>Circulation</i> , 2007, 116, 2216-2233.	1.6	734
182	Cardiac Improvement During Mechanical Circulatory Support. <i>Circulation</i> , 2007, 115, 2497-2505.	1.6	376
183	Clinical Evaluation of the CorCap Cardiac Support Device in Patients With Dilated Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1226-1235.	1.3	128
184	Sustained Benefits of the CorCap Cardiac Support Device on Left Ventricular Remodeling: Three Year Follow-up Results From the Acorn Clinical Trial. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1236-1242.	1.3	105
185	The Impact of Hypogammaglobulinemia on Infection Outcome in Patients Undergoing Ventricular Assist Device Implantation. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 820-824.	0.6	24
186	Molecular Testing in the Management of Cardiac Transplant Recipients: Initial Clinical Experience. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1389-1395.	0.6	114
187	The impact of left ventricular reconstruction on survival in patients with ischemic cardiomyopathy. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 753-759.	1.4	43
188	Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients: Flawed Model or a Model for Future Use?. <i>American Journal of Transplantation</i> , 2005, 5, 2330-2330.	4.7	0
189	Residual high incidence of ventricular arrhythmias after left ventricular reconstructive surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2005, 130, 1250-1256.	0.8	38
190	Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure-Effect Modeling. <i>American Journal of Transplantation</i> , 2004, 4, 2126-2131.	4.7	73
191	Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 185-192.	1.7	55
192	Contemporary outcomes of outpatients referred for cardiac transplantation evaluation to a tertiary heart failure center: impact of surgical alternatives. <i>Journal of Cardiac Failure</i> , 2004, 10, 273-278.	1.7	24
193	Worldwide clinical experience with the CorCap [®] Cardiac Support Device. <i>Journal of Cardiac Failure</i> , 2004, 10, S225-S233.	1.7	49
194	Surgical remodeling in ischemic cardiomyopathy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2003, 5, 311-319.	0.9	6
195	Persistent abnormal left ventricular systolic torsion in dilated cardiomyopathy after partial left ventriculectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003, 126, 48-55.	0.8	63
196	Noninvasive assessment of cardiac mechanics and clinical outcome after partial left ventriculectomy. <i>Annals of Thoracic Surgery</i> , 2003, 76, 1576-1585.	1.3	17
197	Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. <i>New England Journal of Medicine</i> , 2003, 349, 847-858.	27.0	1,104
198	Improving care of chronic heart failure: advances from drugs to devices.. <i>Cleveland Clinic Journal of Medicine</i> , 2003, 70, 141-146.	1.3	2

#	ARTICLE	IF	CITATIONS
199	Myocardial Ischemic Injury After Heart Transplantation Is Associated With Upregulation of Vitronectin Receptor ($\alpha v \beta 3$), Activation of the Matrix Metalloproteinase Induction System, and Subsequent Development of Coronary Vasculopathy. <i>Circulation</i> , 2002, 105, 1955-1961.	1.6	41
200	Introduction: Cardiac Surgery for Heart Failure. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2002, 14, 122-124.	0.6	6
201	The role of vitronectin receptor ($\alpha v \beta 3$) and tissue factor in the pathogenesis of transplant coronary vasculopathy. <i>Journal of the American College of Cardiology</i> , 2002, 39, 804-810.	2.8	25
202	Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. <i>Journal of the American College of Cardiology</i> , 2002, 39, 970-977.	2.8	67
203	Computerized scoring of histopathology for predicting coronary vasculopathy, validated by intravascular ultrasound. <i>Journal of Heart and Lung Transplantation</i> , 2002, 21, 850-859.	0.6	21
204	Management of the Waiting List for Cadaveric Kidney Transplants. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 528-535.	6.1	95
205	Cellular rejection and rate of progression of transplant vasculopathy: a 3-year serial intravascular ultrasound study. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 393-398.	0.6	58
206	Partial left ventriculectomy for dilated cardiomyopathy: Is this an alternative to transplantation?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 121, 879-893.	0.8	138
207	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. <i>Circulation</i> , 2001, 103, 2254-2259.	1.6	515
208	Results of partial left ventriculectomy for dilated cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2098-2103.	2.8	62
209	Outcome of De Novo hepatitis C virus infection in heart transplant recipients. <i>Hepatology</i> , 1999, 30, 1293-1298.	7.3	79
210	Partial left ventriculectomy: sunrise or sunset?. <i>European Journal of Heart Failure</i> , 1999, 1, 313-317.	7.1	15
211	Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure ¹ . <i>European Journal of Cardio-thoracic Surgery</i> , 1998, 13, 337-343.	1.4	120
212	Early results with partial left ventriculectomy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1997, 114, 755-765.	0.8	231